



# *Scientia Veritas, L.L.P.*

---

*5910 Northwood Drive*

*Evergreen, CO 80439*

*www.ScientiaVeritas.com*

*Healthcare: (303) 674-3732*

*Toxicology/Risk Assessment: (303) 674-8751*

*Facsimile: (303) 674-8755*

# **STROKE MANAGEMENT MARKETS AND STRATEGIES**

**APRIL 2003**

Executive Vice President and President, Healthcare:  
Chief Analyst for Report:  
Report Number:

Patricia DeGrandchamp  
Mary Anne Crandall  
SV-101

**Stroke Management Markets and Strategies** has been researched, written, edited, and published by Scientia Veritas, L.L.P. This report is copyrighted and may not be reproduced in any form, in part or in whole, by any means without written permission of Scientia Veritas, L.L.P. This restriction also applies to the purchaser, which may not make copies or reproductions for internal use. Redistribution or resale of illegal copies is strictly forbidden in accordance with U.S. and international laws.

The market research reports published by Scientia Veritas, L.L.P., are intended to provide a thorough analysis of the market in question, including historical, current, and projected sales; competitor analysis; and issues and trends affecting the market. Every effort is made to ensure that data is obtained from accurate sources, all information is correct, and analyses are reasonable, resulting in a current and thorough report at the time of publication. Scientia Veritas will make every effort to include information on important developments in the market that occur after publication in the form of addenda or updates.

Scientia Veritas, L.L.P., offers a full line of healthcare information services, including market research reports, writing of book chapters and journal articles, and custom research.

**SCIENTIA VERITAS, L.L.P.**

5910 Northwood Drive  
Evergreen, CO 80439

Healthcare: (303) 674-3732; Toxicology: (303) 674-8751

Fax: (303) 674-8755

Website: <http://www.scientiaveritas.com>

E-mail: [info@scientiaveritas.com](mailto:info@scientiaveritas.com)

# TABLE OF CONTENTS

<b>TABLE OF CONTENTS .....</b>	<b>I</b>
<b>LIST OF EXHIBITS .....</b>	<b>VII</b>
<b>1 EXECUTIVE SUMMARY .....</b>	<b>1</b>
1.1 Introduction to Stroke and Stroke Management.....	1
1.1.1 Scope and Objectives of Report .....	1
1.1.2 Methodology .....	1
1.1.3 Importance of Stroke Management .....	2
1.1.4 Reasons for Stroke Management Study .....	2
1.1.5 Types of Stroke .....	3
1.1.6 Incidence .....	4
1.1.7 Mortality.....	4
1.2 Issues and Trends in Stroke Management.....	7
1.2.1 Aging of the Population and Demographics .....	7
1.2.2 Education.....	13
1.2.3 Patient Outcomes Research Studies .....	13
1.3 Costs of Stroke .....	14
1.4 Stroke Diagnostics.....	15
1.4.1 Overview .....	15
1.4.2 Procedure Volumes .....	17
1.5 Stroke Pharmaceuticals .....	18
1.5.1 Description of Products.....	18
1.6 Stroke Prevention and Treatment Devices .....	18
1.6.1 Description of Products.....	18
1.7 Surgical Interventions for Stroke .....	19
1.7.1 Description of Surgical Procedures .....	19
1.7.2 Procedural Volumes .....	20
1.8 Market Summary.....	20
1.8.1 Introduction and Overview.....	20
1.8.2 The U.S. Stroke Management Market.....	21
1.8.3 Market Analysis .....	24
<b>2 INTRODUCTION TO STROKE AND STROKE MANAGEMENT .....</b>	<b>25</b>
2.1 Scope and Objectives of Report .....	25

2.2	Methodology .....	25
2.3	Importance of Stroke Management.....	26
2.4	Reasons for Stroke Management Study .....	26
2.5	History of Stroke.....	27
2.6	Description of Stroke .....	27
2.7	Types of Stroke .....	28
2.7.1	Hemorrhagic Stroke .....	29
2.7.1.1	Types of Hemorrhagic Stroke.....	30
2.7.1.2	Symptoms .....	31
2.7.1.3	Early Intervention .....	31
2.7.1.4	Hemorrhagic Stroke Progression .....	31
2.7.1.5	Diagnosis .....	32
2.7.1.6	Treatment.....	32
2.7.1.7	Risk Factors .....	33
2.7.2	Ischemic Stroke.....	34
2.7.2.1	Types of Ischemic Stroke .....	34
2.7.2.2	Symptoms .....	36
2.7.2.3	Early Intervention .....	36
2.7.2.4	Ischemic Stroke Progression.....	37
2.7.2.5	Diagnosis .....	38
2.7.2.6	Treatment.....	38
2.7.2.7	Risk Factors .....	40
2.7.2.8	Prevention.....	42
2.8	Transient Ischemic Attacks.....	43
2.9	Stroke Assessment Scales .....	44
2.10	Incidence, Incidence Rate, and Mortality .....	44
2.10.1	Incidence.....	45
2.10.2	Incidence Rate.....	46
2.10.3	Mortality .....	51
<b>3</b>	<b>ISSUES AND TRENDS IN STROKE MANAGEMENT .....</b>	<b>67</b>
3.1	Aging of the Population and Demographics.....	67
3.2	Education .....	101
3.3	Stroke Prevention Guidelines .....	102
3.4	Stroke Units .....	103
3.5	Patient Outcomes Research Studies.....	104
3.5.1	Cell Therapeutics .....	105
3.6	Rehabilitation.....	106
3.7	Role of the Neuroradiologist.....	107
3.8	Legislative Action.....	108
3.9	Reimbursement .....	109
3.9.1	Medicare/Medicaid.....	109
3.9.2	Managed Care .....	111
3.9.3	Fee-for-Service .....	112
3.10	Home Care Expenditures .....	112
3.11	Long-Term Care Expenditures .....	112
3.12	Costs of Stroke.....	118

<b>4</b>	<b>STROKE DIAGNOSTICS .....</b>	<b>129</b>
4.1	Overview .....	129
4.2	Cerebral Angiography .....	129
4.3	Computed Tomography.....	130
4.4	Magnetic Resonance Angiography .....	130
4.5	Magnetic Resonance Imaging .....	130
4.5.1	Diffusion-weighted Imaging .....	131
4.5.2	Perfusion-weighted Imaging .....	131
4.5.3	Magnetic Resonance Spectroscopy .....	132
4.5.4	Functional Magnetic Resonance Imaging .....	132
4.5.5	Magnetoencephalography .....	132
4.6	Positron Emission Tomography and Radionuclide Single-Photon Computed Tomography .....	133
4.7	Ultrasound .....	134
4.7.1	Transcranial Doppler Ultrasound .....	134
4.7.2	Duplex Carotid Ultrasound .....	134
4.7.3	Photopic Imaging .....	135
4.8	Procedure Volumes .....	135
4.8.1	Cerebral Angiography .....	143
4.8.2	CT of Head and Neck .....	143
4.8.3	MRA of Head and Neck.....	148
4.8.4	MRI of Head and Neck .....	148
4.8.5	PET and SPECT .....	148
4.8.6	Ultrasound of Head and Neck .....	155
4.9	Market Size and Forecast .....	155
4.10	Market Analysis .....	160
<b>5</b>	<b>STROKE PHARMACEUTICALS .....</b>	<b>163</b>
5.1	Description of Products .....	163
5.2	Stroke Prevention Products .....	164
5.2.1	Anticoagulants and Antiplatelet Agents .....	164
5.2.2	Antiarrhythmic Agents .....	166
5.2.3	Antihypertensives.....	167
5.2.4	Statins .....	167
5.3	Stroke Treatment Products .....	168
5.3.1	Anticoagulants.....	168
5.3.2	Neuroprotectants .....	168
5.3.3	Thrombolytics .....	168
5.4	Research and Development .....	170
5.4.1	Anticoagulants and Antiplatelet Drugs .....	176
5.4.2	Antihypertensives.....	177
5.4.3	Neuroprotectants .....	178
5.4.4	Thrombolytics .....	182
5.4.5	Other.....	183
5.5	Market Size and Forecast .....	184
5.5.1	Stroke Prevention Pharmaceuticals .....	189
5.5.2	Stroke Treatment Pharmaceuticals .....	190

5.6	Competitor Analysis .....	195
5.7	Market Analysis .....	198
<b>6</b>	<b>STROKE PREVENTION AND TREATMENT DEVICES.....</b>	<b>199</b>
6.1	Description of Products .....	199
6.2	Catheter-delivered Products.....	206
6.2.1	Balloons .....	206
6.2.2	Coils.....	207
6.2.3	Stents.....	208
6.2.4	Polyvinyl Alcohol.....	212
6.2.5	Acrylic-based Glues.....	213
6.3	Microcatheters .....	213
6.4	Guidewires and Accessories .....	214
6.5	Aneurysm Clips .....	215
6.6	Procedure Volumes.....	216
6.6.1	Catheter-delivered Products.....	216
6.6.2	Microcatheters .....	221
6.6.3	Guidewires and Accessories .....	221
6.6.4	Aneurysm Clips .....	226
6.7	Research and Development.....	226
6.7.1	Atrial Fibrillation Devices .....	231
6.7.2	Hypothermia Devices .....	231
6.7.3	Thrombolytic Devices.....	233
6.7.3.1	Clot Excision Devices.....	233
6.7.3.2	Clot Retrieval Devices.....	234
6.7.3.3	Lasers .....	234
6.7.3.4	Saline Jets .....	234
6.7.3.5	Suction .....	235
6.7.3.6	Ultrasound.....	235
6.7.4	Other Miscellaneous Devices and Treatments.....	235
6.8	Market Size and Forecast.....	236
6.8.1	Catheter-delivered Products.....	237
6.8.2	Microcatheters .....	242
6.8.3	Guidewires and Accessories .....	242
6.8.4	Aneurysm Clips .....	242
6.9	Competitor Analysis .....	251
6.9.1	Catheter-delivered Products.....	252
6.9.2	Microcatheters .....	252
6.9.3	Guidewires and Accessories .....	252
6.9.4	Aneurysm Clips .....	252
6.10	Market Analysis .....	261
<b>7</b>	<b>SURGICAL INTERVENTIONS FOR STROKE.....</b>	<b>263</b>
7.1	Description of Surgical Procedures .....	263
7.1.1	Carotid Endarterectomy .....	263
7.1.2	Extracranial/Intracranial Bypass.....	264

7.1.3	Stereotactic Microsurgery .....	265
7.1.4	Stereotactic Radiosurgery .....	265
7.2	Procedural Volumes .....	265
7.3	Research and Development .....	266
7.4	Market Size and Forecast .....	269
7.5	Market Analysis .....	269
<b>8</b>	<b>MARKET SUMMARY .....</b>	<b>273</b>
8.1	Introduction and Overview .....	273
8.2	The U.S. Stroke Management Market .....	273
8.2.1	Diagnosis .....	282
8.2.2	Pharmaceuticals .....	283
8.2.3	Devices .....	283
8.2.4	Surgical Interventions .....	284
8.3	Market Trends .....	284
8.4	Market Analysis .....	285
<b>9</b>	<b>CORPORATE PROFILES.....</b>	<b>287</b>
9.1	Aesculap, Inc. ....	288
9.1.1	History and Operations .....	288
9.1.2	Stroke Products .....	288
9.1.3	Financial Information .....	288
9.1.4	Research and Development .....	289
9.1.5	Corporate Strategies .....	289
9.2	Bayer Pharmaceutical Division .....	290
9.2.1	History and Operations .....	290
9.2.2	Stroke Products .....	290
9.2.3	Financial Information .....	291
9.2.4	Research and Development .....	292
9.2.5	Corporate Strategies .....	293
9.3	Boston Scientific Corporation .....	294
9.3.1	History and Operations .....	294
9.3.2	Stroke Products .....	295
9.3.3	Financial Information .....	297
9.3.4	Research and Development .....	298
9.3.5	Corporate Strategies .....	299
9.4	Bristol-Myers Squibb Company .....	300
9.4.1	History and Operations .....	300
9.4.2	Stroke Products .....	300
9.4.3	Financial Information .....	301
9.4.4	Research and Development .....	303
9.4.5	Corporate Strategies .....	303
9.5	Cook, Inc. ....	305
9.5.1	History and Operations .....	305
9.5.2	Stroke Products .....	307
9.5.3	Financial Information .....	307

9.5.4	Research and Development .....	308
9.5.5	Corporate Strategies.....	308
9.6	Cordis Corporation .....	309
9.6.1	History and Operations .....	309
9.6.2	Stroke Products .....	310
9.6.3	Financial Information .....	310
9.6.4	Research and Development .....	311
9.6.5	Corporate Strategies.....	312
9.7	Genentech, Inc. ....	313
9.7.1	History and Operations .....	313
9.7.2	Stroke Products .....	314
9.7.3	Financial Information .....	314
9.7.4	Research and Development .....	315
9.7.5	Corporate Strategies.....	316
9.8	Guidant Corporation .....	317
9.8.1	History and Operations .....	317
9.8.2	Stroke Products .....	318
9.8.3	Financial Information .....	319
9.8.4	Research and Development .....	321
9.8.5	Corporate Strategies.....	321
9.9	Medtronic, Inc.....	323
9.9.1	History and Operations .....	323
9.9.2	Stroke Products .....	325
9.9.3	Financial Information .....	326
9.9.4	Research and Development .....	327
9.9.5	Corporate Strategies.....	328
9.10	Roche Group.....	329
9.10.1	History and Operations .....	329
9.10.2	Stroke Products .....	330
9.10.3	Financial Information .....	330
9.10.4	Research and Development .....	331
9.10.5	Corporate Strategies.....	332

**APPENDIX A      COMPANY NAMES AND ADDRESSES..... 333**

# LIST OF EXHIBITS

**TABLE OF CONTENTS ..... I**

**LIST OF EXHIBITS .....VII**

**1 EXECUTIVE SUMMARY ..... 1**

Exhibit 1.1: U.S. Stroke Incidence, by Type, 2001—Number, Share of Total, and Incidence Rate [Table Includes Hemorrhagic (Intracerebral Hemorrhage and Subarachnoid Hemorrhage) and Ischemic (Thrombotic, Embolic, and Lacunar) Strokes] ..... 5

Exhibit 1.2: U.S. Deaths from Cerebrovascular Diseases, 1995-2000—Number and Death Rate per 100,000 Population [Table] ..... 6

Exhibit 1.3: Projections of the Population Aged 65 Years and Over, by Sex and Race for the United States, 1995 to 2050 [Table Includes White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander] ..... 9

Exhibit 1.4: Projections of the Population Aged 85 Years and Over, by Sex and Race for the United States, 1995 to 2050 [Table Includes White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander] ..... 10

Exhibit 1.5: Projections of the Population Aged 100 Years and Over, by Sex and Race for the United States, 1995 to 2050 [Table Includes White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander] ..... 11

Exhibit 1.6: U.S. Population Aged 65 and Over, 85 and Over, and 100 and Over, and Share of Total U.S. Population, 1990-2050 [Table Includes Population Figures and Shares of Total Population] ..... 12

Exhibit 1.7: Lifetime U.S. Cost of First Strokes, by Age Group and Type of Expenditure, 1998 [Table Includes Patients Aged < 65 and ≥ 65 Years, and Direct and Indirect Costs] ..... 16

Exhibit 1.8: The U.S. Market for Stroke Management, by Market Segment, 1996, 2001, and 2006 [Table Includes Diagnosis, Pharmaceuticals, Devices, and Surgical Interventions] ..... 22

Exhibit 1.9: The U.S. Market for Stroke Management, by Market Segment, 2001 [Pie Chart Depicts Diagnosis, Pharmaceuticals, Devices, and Surgical Interventions] ..... 23

**2 INTRODUCTION TO STROKE AND STROKE MANAGEMENT ..... 25**

Exhibit 2.1: U.S. Stroke Incidence, by Type, 2001—Number, Share of Total, and Incidence Rate [Table Includes Hemorrhagic (Intracerebral Hemorrhage and Subarachnoid Hemorrhage) and Ischemic (Thrombotic, Embolic, and Lacunar) Strokes] ..... 47

Exhibit 2.2: U.S. Stroke Incidence, by Type and Share of Total, 2001 [Pie Chart Depicts Hemorrhagic (Intracerebral Hemorrhage and Subarachnoid Hemorrhage) and Ischemic (Thrombotic, Embolic, and Lacunar) Stroke] .....	48
Exhibit 2.3: U.S. Incidence of Hemorrhagic Stroke, by Type, 2001 [Pie Chart Depicts Intracerebral Hemorrhage and Subarachnoid Hemorrhage] .....	49
Exhibit 2.4: U.S. Incidence of Ischemic Stroke, by Type, 2001 [Pie Chart Depicts Thrombotic Stroke, Embolic Stroke, and Lacunar Stroke] .....	50
Exhibit 2.5: U.S. Deaths from Cerebrovascular Diseases, 1995-2000—Number and Death Rate per 100,000 Population [Table] .....	53
Exhibit 2.6: U.S. Deaths from Cerebrovascular Diseases, 1995-2000—Death Rate per 100,000 Population [Bar Chart] .....	54
Exhibit 2.7: U.S. Deaths from Cerebrovascular Diseases, 1998-2000—Number and Death Rate per 100,000 Population, by Age Group [Table Describes Number of Deaths and Death Rates for Ages Under 1, 1 to 4 Years, 5 to 14 Years, 15 to 24 Years, 25 to 44 Years, 45 to 64 Years, and 65 and Over] .....	55
Exhibit 2.8: U.S. Deaths from Cerebrovascular Diseases, 1998-2000—Number, by Age Group [Column Chart Depicts Number of Deaths for Ages Under 1, 1 to 4 Years, 5 to 14 Years, 15 to 24 Years, 25 to 44 Years, 45 to 64 Years, and 65 and Over] .....	56
Exhibit 2.9: U.S. Deaths from Cerebrovascular Diseases, 2000—Percentage by Age Group [Pie Chart Depicts Percentage of Deaths for Ages Under 1, 1 to 4 Years, 5 to 14 Years, 15 to 24 Years, 25 to 44 Years, 45 to 64 Years, and 65 and Over] .....	57
Exhibit 2.10: U.S. Deaths from Cerebrovascular Diseases, 1999—Number and Death Rate per 100,000 Population, by Age Group [Table Describes Number of Deaths and Death Rates for Ages Under 1, 1 to 4 Years, 5 to 14 Years, 15 to 24 Years, 25 to 34 Years, 35 to 44 Years, 45 to 54 Years, 55 to 64 Years, 65 to 74 Years, 75 to 84 Years, and 85 and Over] .....	58
Exhibit 2.11: U.S. Deaths from Cerebrovascular Diseases, 1999—Number, by Age Group [Pie Chart Depicts Number of Deaths for Ages Under 1, 1 to 4 Years, 5 to 14 Years, 15 to 24 Years, 25 to 34 Years, 35 to 44 Years, 45 to 54 Years, 55 to 64 Years, 65 to 74 Years, 75 to 84 Years, and 85 and Over] .....	59
Exhibit 2.12: U.S. Deaths from Cerebrovascular Diseases, 1999—Number of Deaths, Death Rate per 100,000 Population, and Age-Adjusted Death Rate per 100,000 Population, by Race and Sex [Table Describes Number of Deaths, Death Rates, and Age-Adjusted Death Rates for White, Black, and All Other Americans, by Sex] .....	60
Exhibit 2.13: U.S. Deaths from Cerebrovascular Diseases, 1999—Death Rate per 100,000 Population and Age-Adjusted Death Rate per 100,000 Population, by Race and Sex [Line Chart Depicts Death Rates and Age-Adjusted Death Rates for White, Black, and All Other Americans, by Sex] .....	61
Exhibit 2.14: U.S. Deaths from Cerebrovascular Diseases, 1999—Number of Deaths, Death Rate per 100,000 Population, and Age-Adjusted Death Rate per 100,000 Population, by Hispanic and Non-Hispanic Status [Table Describes Number of Deaths, Death Rates, and Age-Adjusted Death Rates for Hispanic and Non-Hispanic Americans, by Sex] .....	62
Exhibit 2.15: U.S. Deaths from Cerebrovascular Diseases, 1999—Death Rate per 100,000 Population and Age-Adjusted Death Rate per 100,000 Population, by Hispanic and Non-Hispanic Status [Line Chart Depicts Death Rates and Age-Adjusted Death Rates for Hispanic and Non-Hispanic Americans, by Sex] .....	63

Exhibit 2.16: Excess Deaths Associated with Stroke, by Race/Ethnicity and Age Group— United States, 1997 .....	64
Exhibit 2.17: Deaths Rates Associated with Stroke, by Race/Ethnicity and Age Group— United States, 1997 [Non-Hispanic White, Non-Hispanic Black, American Indian/Alaska Native, Asian/Pacific Islander, and Hispanic: 35-44, 45-54, 55-64, 65- 74, 75-84, and $\geq 85$ ] .....	65
<b>3 ISSUES AND TRENDS IN STROKE MANAGEMENT .....</b>	<b>67</b>
Exhibit 3.1: U.S. Population Aged 45 to 64 Years, by Race and Hispanic Origin, 1990-2050 [Table Includes White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander Races; and Hispanic Origin].....	71
Exhibit 3.2: U.S. Population Aged 45 to 64 Years, by Race and Hispanic Origin, 1990-2050 [Column Chart Depicts White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander Races; and Hispanic Origin].....	72
Exhibit 3.3: U.S. Population Aged 65 Years and Over, by Race and Hispanic Origin, 1990- 2050 [Table Includes White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander Races; and Hispanic Origin].....	73
Exhibit 3.4: U.S. Population Aged 65 Years and Over, by Race and Hispanic Origin, 1990- 2050 [Column Chart Depicts White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander Races; and Hispanic Origin].....	74
Exhibit 3.5: U.S. Population Aged 85 Years and Over, by Race and Hispanic Origin, 1990- 2050 [Table Includes White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander Races; and Hispanic Origin].....	75
Exhibit 3.6: U.S. Population Aged 85 Years and Over, by Race and Hispanic Origin, 1990- 2050 [Column Chart Depicts Includes White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander Races; and Hispanic Origin].....	76
Exhibit 3.7: U.S. Population Aged 100 Years and Over, by Race and Hispanic Origin, 1990- 2050 [Table Includes White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander Races; and Hispanic Origin].....	77
Exhibit 3.8: U.S. Population Aged 100 Years and Over, by Race and Hispanic Origin, 1990- 2050 [Column Chart Depicts Includes White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander Races; and Hispanic Origin].....	78
Exhibit 3.9: Projections of the Population Aged 65 Years and Over, by Sex and Race for the United States, 1995 to 2050 [Table Includes White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander] .....	79
Exhibit 3.10: Projections of the Population Aged 65 Years and Over, Percent Distribution by Race for the United States, 1995 to 2050 [Table Includes White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander].....	80
Exhibit 3.11: Projections of the Population Aged 65 Years and Over, by Race for the United States, 1995 to 2050 [Column Chart Depicts White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander].....	81
Exhibit 3.12: Projections of the Population Aged 65 Years and Over, by Sex, Race, and Hispanic Origin for the United States, 1995 to 2050 [Table Includes Hispanic Origin and Non-Hispanic White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander].....	82

Exhibit 3.13: Projections of the Population Aged 65 Years and Over, Percent Distribution by Race, and Hispanic Origin for the United States, 1995 to 2050 [Table Includes Hispanic Origin and Non-Hispanic White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander] .....	83
Exhibit 3.14: Projections of the Population Aged 65 Years and Over, by Race, and Hispanic Origin for the United States, 1995 to 2050 [Column Chart Depicts Hispanic Origin and Non-Hispanic White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander] .....	84
Exhibit 3.15: Projections of the Population Aged 65 Years and Over, by Sex for the United States, 1995 to 2050 [Column Chart Depicts Male and Female].....	85
Exhibit 3.16: Projections of the Population Aged 85 Years and Over, by Sex and Race for the United States, 1995 to 2050 [Table Includes White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander].....	86
Exhibit 3.17: Projections of the Population Aged 85 Years and Over, Percent Distribution by Race for the United States, 1995 to 2050 [Table Includes White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander] .....	87
Exhibit 3.18: Projections of the Population Aged 85 Years and Over, by Race for the United States, 1995 to 2050 [Column Chart Depicts White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander] .....	88
Exhibit 3.19: Projections of the Population Aged 85 Years and Over, by Sex, Race, and Hispanic Origin for the United States, 1995 to 2050 [Table Includes Hispanic Origin and Non-Hispanic White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander] .....	89
Exhibit 3.20: Projections of the Population Aged 85 Years and Over, Percent Distribution by Race, and Hispanic Origin for the United States, 1995 to 2050 [Table Includes Hispanic Origin and Non-Hispanic White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander] .....	90
Exhibit 3.21: Projections of the Population Aged 85 Years and Over, by Race, and Hispanic Origin for the United States, 1995 to 2050 [Column Chart Depicts Hispanic Origin and Non-Hispanic White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander] .....	91
Exhibit 3.22: Projections of the Population Aged 85 Years and Over, by Sex for the United States, 1995 to 2050 [Column Chart Depicts Male and Female].....	92
Exhibit 3.23: Projections of the Population Aged 100 Years and Over, by Sex and Race for the United States, 1995 to 2050 [Table Includes White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander] .....	93
Exhibit 3.24: Projections of the Population Aged 100 Years and Over, Percent Distribution by Race for the United States, 1995 to 2050 [Table Includes White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander] .....	94
Exhibit 3.25: Projections of the Population Aged 100 Years and Over, by Race for the United States, 1995 to 2050 [Column Chart Depicts White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander] .....	95
Exhibit 3.26: Projections of the Population Aged 100 Years and Over, by Sex, Race, and Hispanic Origin for the United States, 1995 to 2050 [Table Includes Hispanic Origin and Non-Hispanic White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander] .....	96

Exhibit 3.27: Projections of the Population Aged 100 Years and Over, Percent Distribution by Race, and Hispanic Origin for the United States, 1995 to 2050 [Table Includes Hispanic Origin and Non-Hispanic White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander].....	97
Exhibit 3.28: Projections of the Population Aged 100 Years and Over, by Race, and Hispanic Origin for the United States, 1995 to 2050 [Column Chart Depicts Hispanic Origin and Non-Hispanic White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander].....	98
Exhibit 3.29: Projections of the Population Aged 100 Years and Over, by Sex for the United States, 1995 to 2050 [Column Chart Depicts Male and Female].....	99
Exhibit 3.30: U.S. Population Aged 65 and Over, 85 and Over, and 100 and Over, and Share of Total U.S. Population, 1990-2050 [Table Includes Population Figures and Shares of Total Population] .....	100
Exhibit 3.31: National Home Health Care Expenditures, by Source of Funds, 1996-2010 [Table Includes Out-of-Pocket Payments, Private Health Insurance, Other Private Funds, Federal Payments, and State and Local Payments] .....	114
Exhibit 3.32: National Home Health Care Expenditures, by Source of Funds, 1996-2010 [Line Chart Depicts Out-of-Pocket Payments, Private Health Insurance, Other Private Funds, Federal Payments, and State and Local Payments] .....	115
Exhibit 3.33: National Nursing Home Care Expenditures, by Source of Funds, 1996-2010 [Table Includes Out-of-Pocket Payments, Private Health Insurance, Other Private Funds, Federal Payments, and State and Local Payments] .....	116
Exhibit 3.34: National Nursing Home Care Expenditures, by Source of Funds, 1996-2010 [Line Chart Depicts Out-of-Pocket Payments, Private Health Insurance, Other Private Funds, Federal Payments, and State and Local Payments] .....	117
Exhibit 3.35: Lifetime U.S. Cost of First Strokes, by Age Group and Type of Expenditure, 1998 [Table Includes Patients Aged < 65 and ≥ 65 Years, and Direct and Indirect Costs].....	120
Exhibit 3.36: Lifetime Direct, Indirect, and Total Net Cost per U.S. Elderly Ischemic Stroke Patient, by Age, Sex, and Race, for 1991 Incidence Cohort of Hospitalized Cases [Table Includes White Males, Non-White Males, White Females, and Non-White Females, Aged 65-69, 75-79, 80-85, and 85 and Over] .....	121
Exhibit 3.37: Lifetime Direct, Indirect, and Total Net Cost per U.S. Elderly ICH Stroke Patient, by Age, Sex, and Race, for 1991 Incidence Cohort of Hospitalized Cases [Table Includes White Males, Non-White Males, White Females, and Non-White Females, Aged 65-69, 75-79, 80-85, and 85 and Over] .....	122
Exhibit 3.38: Lifetime Direct, Indirect, and Total Net Cost per U.S. Elderly SAH Stroke Patient, by Age, Sex, and Race, for 1991 Incidence Cohort of Hospitalized Cases [Table Includes White Males, Non-White Males, White Females, and Non-White Females, Aged 65-69, 75-79, 80-85, and 85 and Over] .....	123
Exhibit 3.39: Aggregated Two-Year Ischemic Stroke Direct Cost, by Category [Pie Chart Depicts Acute Hospitalization, Direct Nonmedical, Durable Medical Equipment, Home Health, Inpatient Rehabilitation, Nursing Home, Outpatient Drug, Physician and Other Medicare Part B, and Skilled Nursing Facility] .....	124
Exhibit 3.40: Aggregated Two-Year Hemorrhagic Stroke Direct Cost, by Category [Pie Chart Depicts Acute Hospitalization, Direct Nonmedical, Durable Medical Equipment, Home Health, Inpatient Rehabilitation, Nursing Home, Outpatient Drug, Physician and Other Medicare Part B, and Skilled Nursing Facility] .....	125

Exhibit 3.41: Ischemic Stroke Survival Among U.S. Patients Aged 65 and Over, by Age, Sex, and Race [Table Includes White Males, Non-White Males, White Females, and Non-White Females, Aged 65-69, 75-79, 80-85, and 85 and Over].....	126
Exhibit 3.42: Hemorrhagic Stroke Survival Among U.S. Patients Aged 65 and Over, by Age, Sex, and Race [Table Includes White Males, Non-White Males, White Females, and Non-White Females, Aged 65-69, 75-79, 80-85, and 85 and Over].....	127
<b>4 STROKE DIAGNOSTICS .....</b>	<b>129</b>
Exhibit 4.1: U.S. Stroke Diagnostic Procedure Volumes and Reimbursements, by Type of Procedure, 2001 [Table Includes Cerebral Angiography, CT, MRA, PET and SPECT, and Ultrasound].....	137
Exhibit 4.2: Percent Distribution of U.S. Stroke Diagnostic Procedure Volumes, by Type, 2001 [Pie Chart Depicts Cerebral Angiography, CT, MRA, PET and SPECT, and Ultrasound].....	138
Exhibit 4.3: Percent Distribution of U.S. Stroke Diagnostic Procedure Reimbursements, by Type of Procedure, 2001 [Pie Chart Depicts Cerebral Angiography, CT, MRA, PET and SPECT, and Ultrasound].....	139
Exhibit 4.4: U.S. Stroke Diagnostic Procedure Volumes, by Type, 1996-2006 [Table Includes Cerebral Angiography, CT, MRA, PET and SPECT, and Ultrasound] ...	140
Exhibit 4.5: U.S. Stroke Diagnostic Procedure Volumes, by Type, 1996-2006 [Column Chart Depicts Cerebral Angiography, CT, MRA, PET and SPECT, and Ultrasound].....	141
Exhibit 4.6: Percent Distribution of U.S. Stroke Diagnostic Procedure Volumes, by Type, 1996-2006 [Table Includes Cerebral Angiography, CT, MRA, PET and SPECT, and Ultrasound].....	142
Exhibit 4.7: U.S. Cerebral Angiography Procedures Performed for Stroke Diagnosis, 1996-2006 [Table].....	144
Exhibit 4.8: U.S. Cerebral Angiography Procedures Performed for Stroke Diagnosis, 1996-2006 [Column Chart].....	145
Exhibit 4.9: U.S. Computed Tomography of Head and Neck Procedures Performed for Stroke Diagnosis, 1996-2006 [Table].....	146
Exhibit 4.10: U.S. Computed Tomography of Head and Neck Procedures Performed for Stroke Diagnosis, 1996-2006 [Column Chart].....	147
Exhibit 4.11: U.S. Magnetic Resonance Angiography of Head and Neck Procedures Performed for Stroke Diagnosis, 1996-2006 [Table].....	149
Exhibit 4.12: U.S. Magnetic Resonance Angiography of Head and Neck Procedures Performed for Stroke Diagnosis, 1996-2006 [Column Chart].....	150
Exhibit 4.13: U.S. Magnetic Resonance Imaging of Head and Neck Procedures Performed for Stroke Diagnosis, 1996-2006 [Table].....	151
Exhibit 4.14: U.S. Magnetic Resonance Imaging of Head and Neck Procedures Performed for Stroke Diagnosis, 1996-2006 [Column Chart].....	152
Exhibit 4.15: U.S. Positron Emission Tomography and Radionuclide Single-Photon Emission Computed Tomography Procedures Performed for Stroke Diagnosis, 1996-2006 [Table].....	153
Exhibit 4.16: U.S. Positron Emission Tomography and Radionuclide Single-Photon Emission Computed Tomography Procedures Performed for Stroke Diagnosis, 1996-2006 [Column Chart].....	154

Exhibit 4.17: U.S. Ultrasound of Head and Neck Procedures Performed for Stroke Diagnosis, 1996-2006 [Table].....	156
Exhibit 4.18: U.S. Ultrasound of Head and Neck Procedures Performed for Stroke Diagnosis, 1996-2006 [Column Chart] .....	157
Exhibit 4.19: The U.S. Market for Stroke Diagnosis, 1996-2006 [Table] .....	158
Exhibit 4.20: The U.S. Market for Stroke Diagnosis, 1996-2006 [Column Chart].....	159
<b>5 STROKE PHARMACEUTICALS.....</b>	<b>163</b>
Exhibit 5.1: Clinical Trials of Pharmaceuticals for Stroke Prevention, Stroke Treatment, and Neuroprotection, 2002.....	171
Exhibit 5.2: The U.S. Market for Stroke Pharmaceuticals, by Type, 1996-2006 [Table Includes Stroke Prevention and Stroke Treatment Pharmaceuticals].....	185
Exhibit 5.3: The U.S. Market for Stroke Pharmaceuticals, by Type, 2001 [Pie Chart Depicts Stroke Prevention and Stroke Treatment Pharmaceuticals] .....	186
Exhibit 5.4: The U.S. Market for Stroke Pharmaceuticals, by Type, 1996-2006 [Column Chart Depicts Stroke Prevention and Stroke Treatment Pharmaceuticals] .....	187
Exhibit 5.5: Percent Distribution of U.S. Stroke Pharmaceutical Revenues, by Type, 1996-2006 [Table Includes Stroke Prevention and Stroke Treatment Pharmaceuticals] .	188
Exhibit 5.6: The U.S. Market for Stroke Prevention Pharmaceuticals, 1996-2006 [Table Includes Stroke Prevention Pharmaceuticals] .....	191
Exhibit 5.7: The U.S. Market for Stroke Prevention Pharmaceuticals, 1996-2006 [Column Chart Depicts Stroke Prevention Pharmaceuticals].....	192
Exhibit 5.8: The U.S. Market for Stroke Treatment Pharmaceuticals, 1996-2006 [Table Includes Stroke Treatment Pharmaceuticals] .....	193
Exhibit 5.9: The U.S. Market for Stroke Treatment Pharmaceuticals, 1996-2006 [Column Chart Depicts Stroke Treatment Pharmaceuticals].....	194
Exhibit 5.10: The U.S. Stroke Pharmaceuticals Market: Major Suppliers' Market Shares, 2001 [Table] .....	196
Exhibit 5.11: The U.S. Stroke Pharmaceuticals Market: Major Suppliers' Market Shares, 2001 [Pie Chart] .....	197
<b>6 STROKE PREVENTION AND TREATMENT DEVICES.....</b>	<b>199</b>
Exhibit 6.1: U.S. FDA Approvals of Hemorrhagic Stroke Prevention and Treatment Devices Rated Substantially Equivalent, 1987-2002 .....	201
Exhibit 6.2: Device and Procedure Clinical Trials for Stroke Applications, Ongoing Trials, 2002.....	204
Exhibit 6.3: U.S. Stroke Device Procedure Volumes, by Type, 1996-2006 [Table Includes Catheter-delivered Products, Microcatheters, Guidewires and Accessories, and Aneurysm Clips] .....	217
Exhibit 6.4: U.S. Stroke Device Procedure Volumes, by Type, 1996-2006 [Column Chart Depicts Catheter-delivered Products, Microcatheters, Guidewires, and Aneurysm Clips].....	218
Exhibit 6.5: Percent Distribution of U.S. Stroke Device Procedure Volumes, by Type, 1996-2006 [Table Includes Catheter-delivered Products, Microcatheters, Guidewires, and Aneurysm Clips] .....	219

Exhibit 6.6: Percent Distribution of U.S. Stroke Device Procedure Volumes, by Type, 2001 [Pie Chart Depicts Catheter-delivered Products, Microcatheters, Guidewires, and Aneurysm Clips].....	220
Exhibit 6.7: U.S. Catheter-delivered Product Procedures Performed for Stroke Prevention or Treatment, 1996-2006 [Table].....	222
Exhibit 6.8: U.S. Catheter-delivered Product Procedures Performed for Stroke Prevention or Treatment, 1996-2006 [Column Chart] .....	223
Exhibit 6.9: U.S. Microcatheter Procedures Performed for Stroke Prevention or Treatment, 1996-2006 [Table] .....	224
Exhibit 6.10: U.S. Microcatheter Procedures Performed for Stroke Prevention or Treatment, 1996-2006 [Column Chart].....	225
Exhibit 6.11: U.S. Guidewire and Accessory Procedures Performed for Stroke Prevention or Treatment, 1996-2006 [Table].....	227
Exhibit 6.12: U.S. Guidewire and Accessory Procedures Performed for Stroke Prevention or Treatment, 1996-2006 [Column Chart] .....	228
Exhibit 6.13: U.S. Aneurysm Clip Procedures Performed for Stroke Prevention or Treatment, 1996-2006 [Table] .....	229
Exhibit 6.14: U.S. Aneurysm Clip Procedures Performed for Stroke Prevention or Treatment, 1996-2006 [Column Chart].....	230
Exhibit 6.15: The U.S. Market for Stroke Prevention and Treatment Devices, by Type, 1996-2006 [Table Includes Catheter-delivered Products, Microcatheters, Guidewires and Accessories, and Aneurysm Clips] .....	238
Exhibit 6.16: The U.S. Market for Stroke Prevention and Treatment Devices, by Type, 2001 [Pie Chart Depicts Catheter-delivered Products, Microcatheters, Guidewires and Accessories, and Aneurysm Clips] .....	239
Exhibit 6.17: The U.S. Market for Stroke Prevention and Treatment Devices, by Type, 1996-2006 [Column Chart Depicts Catheter-delivered Products, Microcatheters, Guidewires and Accessories, and Aneurysm Clips] .....	240
Exhibit 6.18: Percent Distribution of U.S. Stroke Prevention and Treatment Device Revenues, by Type, 1996-2006 [Table Includes Catheter-delivered Products, Microcatheters, Guidewires and Accessories, and Aneurysm Clips].....	241
Exhibit 6.19: The U.S. Market for Catheter-delivered Stroke Prevention and Treatment Devices: Units and Revenues, 1996-2006 [Table Includes Unit Sales and Revenues] .....	243
Exhibit 6.20: The U.S. Market for Catheter-delivered Stroke Prevention and Treatment Devices, 1996-2006 [Column Chart Depicts Catheter-delivered Products].....	244
Exhibit 6.21: The U.S. Market for Microcatheters Used for Stroke Prevention and Treatment: Units and Revenues, 1996-2006 [Table Includes Unit Sales and Revenues] .....	245
Exhibit 6.22: The U.S. Market for Microcatheters Used for Stroke Prevention and Treatment, 1996-2006 [Column Chart Depicts Microcatheters].....	246
Exhibit 6.23: The U.S. Market for Guidewires and Accessories Used for Stroke Prevention and Treatment: Units and Revenues, 1996-2006 [Table Includes Unit Sales and Revenues].....	247
Exhibit 6.24: The U.S. Market for Guidewires and Accessories Used for Stroke Prevention and Treatment, 1996-2006 [Column Chart Depicts Guidewires and Accessories] .....	248
Exhibit 6.25: The U.S. Market for Aneurysm Clips Used for Stroke Prevention and Treatment: Units and Revenues, 1996-2006 [Table Includes Unit Sales and Revenues].....	249

Exhibit 6.26: The U.S. Market for Aneurysm Clips Used for Stroke Prevention and Treatment, 1996-2006 [Column Chart Depicts Aneurysm Clips].....	250
Exhibit 6.27: The U.S. Market for Catheter-delivered Products Used for Stroke Prevention and Treatment: Major Suppliers' Market Shares, 2001 [Table].....	253
Exhibit 6.28: The U.S. Market for Catheter-delivered Products Used for Stroke Prevention and Treatment: Major Suppliers' Market Shares, 2001 [Pie Chart].....	254
Exhibit 6.29: The U.S. Market for Microcatheters Used in Stroke Prevention and Treatment: Major Suppliers' Market Shares, 2001 [Table].....	255
Exhibit 6.30: The U.S. Market for Microcatheters Used in Stroke Prevention and Treatment: Major Suppliers' Market Shares, 2001 [Pie Chart].....	256
Exhibit 6.31: The U.S. Market for Guidewires and Accessories Used in Stroke Prevention and Treatment: Major Suppliers' Market Shares, 2001 [Table].....	257
Exhibit 6.32: The U.S. Market for Guidewires and Accessories Used in Stroke Prevention and Treatment: Major Suppliers' Market Shares, 2001 [Pie Chart].....	258
Exhibit 6.33: The U.S. Market for Aneurysm Clips Used in Stroke Prevention and Treatment: Major Suppliers' Market Shares, 2001 [Table].....	259
Exhibit 6.34: The U.S. Market for Aneurysm Clips Used in Stroke Prevention and Treatment: Major Suppliers' Market Shares, 2001 [Pie Chart].....	260
<b>7 SURGICAL INTERVENTIONS FOR STROKE.....</b>	<b>263</b>
Exhibit 7.1: U.S. Procedure Volumes for Stroke Surgical Interventions, 1996-2006 [Table] .....	267
Exhibit 7.2: U.S. Procedure Volumes for Stroke Surgical Interventions, 1996-2006 [Column Chart].....	268
Exhibit 7.3: The U.S. Market for Stroke Surgical Interventions, 1996-2006 [Table].....	270
Exhibit 7.4: The U.S. Market for Stroke Surgical Interventions, 1996-2006 [Column Chart] .....	271
<b>8 MARKET SUMMARY .....</b>	<b>273</b>
Exhibit 8.1: The U.S. Market for Stroke Management, by Market Segment, 1996-2006 [Table Includes Diagnosis, Pharmaceuticals, Devices, and Surgical Interventions].....	275
Exhibit 8.2: The U.S. Market for Stroke Management, by Market Segment, 2001 [Pie Chart Depicts Diagnosis, Pharmaceuticals, Devices, and Surgical Interventions] .....	276
Exhibit 8.3: The U.S. Market for Stroke Management, by Market Segment, 1996-2006 [Column Chart Depicts Diagnosis, Pharmaceuticals, Devices, and Surgical Interventions] .....	277
Exhibit 8.4: The U.S. Market for Stroke Management, by Market Segment and Subsegment, 1996-2006 [Table Includes Diagnosis, Pharmaceuticals (Stroke Prevention, Stroke Treatment), Devices (Catheter-delivered Products, Microcatheters, Guidewires and Accessories, and Aneurysm Clips), and Surgical Interventions] .....	278
Exhibit 8.5: The U.S. Market for Stroke Management, by Market Subsegment, 2001 [Pie Chart Depicts Diagnosis, Stroke Prevention Pharmaceuticals, Stroke Treatment Pharmaceuticals, Catheter-delivered Products, Microcatheters, Guidewires and Accessories, Aneurysm Clips, and Surgical Interventions] .....	279

Exhibit 8.6: The U.S. Market for Stroke Management, by Market Subsegment, 1996-2006 [Column Chart Depicts Diagnosis, Stroke Prevention Pharmaceuticals, Stroke Treatment Pharmaceuticals, Catheter-delivered Products, Microcatheters, Guidewires and Accessories, Aneurysm Clips, and Surgical Interventions] ..... 280

Exhibit 8.7: The U.S. Market for Stroke Management, Percent Distribution by Market Segment and Subsegment, 1996-2006 [Table Includes Diagnosis, Pharmaceuticals (Stroke Prevention, Stroke Treatment), Devices (Catheter-delivered Products, Microcatheters, Guidewires and Accessories, and Aneurysm Clips), and Surgical Interventions] ..... 281